Fragile X associated tremor/ataxia syndrome (FXTAS) is a late onset neurodegenerative disorder caused by aberrant expansion of CGG repeats in 59 UTR of FMR1 gene. The elevated mRNA confers a toxic gain-of-function thought to be the critical event of pathogenesis. Expressing rCGG 90 repeats of the human FMR1 59UTR in Drosophila is sufficient to induce neurodegeneration. Rapamycin has been demonstrated to attenuate neurotoxicity by inducing autophagy in various animal models of neurodegenerative diseases. Surprisingly, we observed rapamycin exacerbated rCGG 90 -induced neurodegenerative phenotypes through an autophagy-independent mechanism. CGG 90 expression levels of FXTAS flies exposed to rapamycin presented no significant differences. We further demonstrated that activation of the mammalian target of rapamycin (mTOR) signaling could suppress neurodegeneration of FXTAS. These findings indicate that rapamycin will exacerbate neurodegeneration, and that enhancing autophagy is insufficient to alleviate neurotoxicity in FXTAS. Moreover, these results suggest mTOR and its downstream molecules as new therapeutic targets for FXTAS by showing significant protection against neurodegeneration.
Introduction
Fragile X associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disease caused by aberrant expansion of CGG repeats in 59 UTR of FMR1 gene. The major clinical features of FXTAS are progressive intention tremor and/or ataxia accompanied by gradual behavioral deficits and cognitive decline [1, 2] . The frequency of fragile X premutation in the general population is approximately 1/813 in males, and about 30%-40% of male FMR1 premutation carriers will ultimately exhibit some features of FXTAS by the time they are over 50 years old [3] . So far, there is no effective therapeutic intervention for FXTAS.
FXTAS results from an RNA toxic gain-of-function, and the accumulation of elevated FMR1 mRNA is believed to be an important and proximal event in pathogenesis. Premutationlength rCGG repeats are sufficient to cause neurodegeneration. An FXTAS Drosophila model that ectopically expresses rCGG 90 repeats of the human FMR1 59UTR presents a series of neurodegenerative phenotypes which could imitate clinical features of FXTAS patients [4] . CGG KI mice have also shown many important aspects of FXTAS, including elevated mRNA levels, presence of intranuclear inclusions, and progressed cognitive and behavioral declines [5, 6, 7] . Neurotoxicity in FXTAS Drosophila and mice models reveal a highly significant association with the length and dosage of CGG tracts, and a stronger expression of rCGG 90 has more severe consequences [4, 8] .
FXTAS is a typical member of trinucleotide repeat expansion diseases (TREDs) carrying FMR1 alleles, called premutation, with 55-200 CGG repeats. Rapamycin has been proven to protect against neurodegeneration by inducing autophagy and removing pathogenic protein aggregates in many experimental models of other TREDs, including Huntington disease (HD), spinocerebellar ataxia type 3 (SCA3) and spinal and bulbar muscular atrophy (SBMA) [9, 10, 11, 12] . As an acknowledged inhibitor of mTOR and inducer of autophagy, rapamycin has also been used in many other neurodegenerative diseases' models, such as Alzheimer's disease (AD) and Parkinson's disease (PD), to induce autophagy, to restore mTOR signaling from hyperactivity to normal levels and to decrease translation [13, 14, 15, 16] . Moreover, induction of autophagy and inhibition of the mTOR pathway have been found in human myoblasts of myotonic dystrophy type 1 (DM1), a noncoding repeat expansion RNA toxicity diseases due to gain-of-function effect of the RNA of the DMPK gene [17] .
As the direct target of rapamycin, mTOR is a highly conserved kinase which acts as a sensor of amino acids, growth factors, energy and stress, and which coordinates cell growth, proliferation, metabolism, and cycle by regulating protein synthesis and autophagy. Sensing the intracellular stress, phosphoinositide 3-kinase (PI3K) activates AKT, a serine/threonine protein kinase also known as Protein Kinase B (PKB), which leads to a series of downstream cascades and ultimately activates mTOR. Once activated, mTOR drives the phosphorylation of downstream substrates, p70-S6 kinase (S6K) and eIF4E-binding protein 1 (4E-BP1), and regulates protein synthesis [9] . Repression of mTOR activity by nucleolar disruption restricted to dopaminergic (DA) neurons has shown progressive and differential loss of DA neurons and locomotor abnormalities that resemble PD while activation of mTOR pathway exerts neuroprotective effect [18, 19] .
Here we sought to determine if FXTAS shares the common pathogenesis with other neurodegenerative diseases and could be treated with rapamycin using a Drosophila model. Surprisingly, we found that rapamycin could not ameliorate phenotypes, but rather led to more severe ones. Exposure to rapamycin didn't cause an increase of rCGG 90 expression levels, and autophagy was ineffective to suppress neurotoxicity. Furthermore, activation of mTOR pathway could improve neurodegenerative phenotypes.
Results

Rapamycin cannot ameliorate but aggravates the neurodegenerative phenotypes in FXTAS Drosophila model
To determine if FXTAS shares similar pharmaceutical or genetic modifiers with other neurodegenerative disorders, we used an established Drosophila model of rCGG repeat induced neurodegeneration. Expressing CGG 90 in the retina using GMR-GAL4 drivers severely disrupted eye morphology as characterized by loss of pigmentation, neuron death (escharosis), retinal collapse, and ommatidial fusion. Expressing CGG 90 ubiquitously using Daughterless-GAL4 drivers shortened lifespan. Expressing CGG 90 in the nervous system using NRV2-GAL4 drivers led to decreased locomotion. Control flies expressing EGFP alone had no observed phenotype.
To examine if rapamycin could suppress neurodegeneration in the FXTAS Drosophila model, we reared flies expressing retinal CGG 90 or EGFP on food supplemented with either a DMSO control or rapamycin at doses known to mitigate neurotoxicity in other neurodegenerative diseases [10, 20] . Significant eye phenotype exacerbations of GMR-GAL4.CGG 90 were observed at 2.5 mM and 5 mM in repeated experiments. Rapamycin increased the appearance and affected areas of eschar, a surrogate marker for severe cell death, and loss-of-pigmentation in the retina (Fig. 1A(i) ). Quantitative analyses of eye phenotypes showed significant difference between rapamycin-treated and untreated flies (p,0.0001, Fig. 1A (ii)). In subsequent experiments, Daughterless-GAL4.CGG 90 and NRV2-GAL4.CGG 90 were fed food containing DMSO or 2.5 mM and 5 mM rapamycin. Consistent with its role in eye phenotype, rapamycin failed to show a protective effect on lifespan and locomotion. Flies exposed to rapamycin presented dramatic reduction of lifetime (Fig. 1B(i) ) and more severe locomotor activity defects (p,0.001, Fig. 1C ) compared to control flies (Fig. 1B(ii), D) . Effects were dosedependent, with treatment at 5 mM rapamycin leading to more severe phenotypes than 2.5 mM. Neurodegeneration in FXTAS Drosophila is extremely severe and irreversible. Treatment of adult flies after eclosion with high doses of rapamycin, 50 mM, 200 mM and 400 mM, previously used to extend lifespan of flies with paraquat [16] , strikingly shortened the lifespan (Fig. 1E ) and low doses had no effect practically.
Since overexpressions of rCGG 90 could induce neurodegeneration with dosage-dependent toxicity in Drosophila, we next investigated if rapamycin altered the mRNA levels of CGG 90 . Realtime PCR was used to quantify the relative level of rCGG 90 transcripts by detecting expression of EGFP which acts as a reporter of CGG 90 . Quantitative analyses showed that treatment with rapamycin didn't increase expression levels of rCGG 90 (Fig. 1F ). In addition, as low doses of rapamycin have been shown to extend lifespan of Drosophila [21] , we assessed the effects of 4 other concentrations, 1 nM, 10 nM, 100 nM and 1 mM, in longevity tests of FXTAS flies. Low doses of rapamycin could mildly extend the lifespan of control flies, but couldn't extend lifespan of FXTAS flies. Analyses of locomotion assays also strongly support the conclusion that low dosages of rapamycin were ineffective to ameliorate neuronal toxicity of FXTAS (data not shown). Thus, rapamycin could not ameliorate but exacerbates neurodegeneration in FXTAS Drosophila model without an increase of rCGG 90 toxicity.
Rapamycin aggravates neurodegenerative phenotypes of FXTAS flies through an autophagy-independent mechanism
Acknowledged as an efficient inducer of autophagy, rapamycin has been shown to have a protective effect against many neurodegenerative diseases. To evaluate whether autophagy is involved in rapamycin's exacerbation of the CGG 90 rough eye phenotype, we performed an RNAi-mediated knockdown of autophagy related genes (Atg 1, 5, 7 and 12 respectively) in GMR-GAL4.CGG 90 to attenuate the induction of autophagy. In contrast to rapamycin's aggravation of rCGG 90 -induced rough eye phenotype, co-expressing Atg RNAis showed no modification to the control phenotype ( Fig. 2A) .
Rilmenidine, an mTOR-independent autophagy-inducer, was administrated at appropriate gradient concentrations according to doses used to attenuate toxicity of polyglutamine expansions in a mouse model [22] . As expected, rilmenidine was as ineffective at modifying the CGG 90 -dependent retina degeneration as RNAi of Atgs (Fig. 2B, D) . Control flies were also not influenced by rilmenidine (Fig. 2C) . The above data indicate that autophagy was not involved in the exacerbation of neurodegenerative phenotypes in FXTAS flies.
Activating mTOR can improve neurodegeneration in FXTAS
Since rapamycin had been generally thought to be the specific inhibitor of mTOR and autophagy had been proven ineffective at altering neurodegeneration in FXTAS, here we examined the activity of mTOR pathway in FXTAS Drosophila model. The activation of mTOR can be measured by phosphorylation of S6K or 4E-BP1, which increases protein translation by activating a ribosomal protein rpS6 and eIF4B and by dissociating from eIF4E respectively. Western blotting analyses were performed using a phospho-Thr398-dependent S6K antibody and a phosphoThr37/46-dependent 4E-BP1 antibody. The activity of the mTOR pathway exhibited no difference in the presence or absence of CGG 90 (Fig. 3A) . To determine the extent of rapamycin inhibited mTOR signaling in FXTAS flies, we measured the phosphorylation of S6K and 4E-BP1 in untreated and rapamycin-treated flies. As predicted, we observed a dosedependent reduction in phospho-T398-S6K and phosphorThr37/46-4E-BP1 levels after rapamycin treatment, confirming that rapamycin suppressed mTOR signaling in FXTAS Drosphila (Fig. 3B) .
To estimate if mTOR could alter neurodegenerative phenotypes, we crossed AKT RNAi and Rheb overexpressed fly lines with GMR-GAL4.CGG 90 as both AKT and Rheb locate upstream of mTOR in the PI3K/AKT/mTOR pathway. As expected, knockdown of AKT by RNAi in GMR-GAL4.CGG 90 enhanced the rCGG 90 -induced eye phenotype (p,0.0001, Fig. 3C b, h and D). Conversely, overexpression of Rheb conferred a protective effect against rough eye (p,0.0001, Fig. 3C c, i and D) . These results indicate that modulating mTOR activity resulted in an alteration of neurodegenerative phenotypes of FXTAS. To further demonstrate that activating mTOR could ameliorate eye phenotypes of FXTAS flies, we overexpressed S6K and 4E-BP1, well-described downstream targets of mTOR, in GMR-GAL4.CGG 90 . Overexpression of 4E-BP1 could prevent ommatidial degeneration efficiently (p,0.0001, Fig. 3C d, i, and E) . Similarly, overexpression of S6K could suppress even severe rough eye phenotypes (p,0.0001, Fig. 3C e, k and E) . We next crossed dominant negative S6K (DN-S6K) with GMR-GAL4.CGG 90 . As expected, DN-S6K expression presented as obvious retinal detriment (p,0.0001, Fig. 3C f, l and E) . Notably, we found a substantial reduction in the viability of flies co-expressing CGG 90 and DN-S6K to compound eye. After eclosion, over 20% GMR-GAL4.CGG 90 +DN-S6K flies exhibited abnormal wings which failed to expand. Western blotting analyses were used to verify the expression levels of S6K and 4E-BP1 (Fig. 3F, G) . Based on these results, we concluded that activation of mTOR signaling could repress neurodegenerative phenotypes of FXTAS.
Discussion
Rapamycin, a neutral macrolide with immunosuppressive properties, has been proven to extend lifespan [16, 21, 23] and to have a protective effect in many neurodegenerative diseases through induction of autophagy. As rapamycin protects against neuron death, alleviates neurotoxicity, and reduces the formation of aggregates in experimental models of other neurodegenerative disorders, we expected to see similar protective effects in FXTAS [24, 25, 26] . Unfortunately, rapamycin did not ameliorate the neurodegenerative phenotypes of FXTAS in our Drosophila model instead aggravating them. Recognized as an arbiter of neuronal survival and death decisions in many neurodegenerative diseases, autophagy is the most crucial cellular process involved in the clearance of redundant proteins and components [27] . Activation of autophagy has been demonstrated to mitigate neurotoxicity by promoting degradation of mutant proteins [11, 25] . Nevertheless, intriguingly, we have shown that autophagy alone has no effect on altering neurodegenerative phenotypes of FXTAS. In a previous study by Todd PK [28] , overexpression of histone deacetylase 6 (HDAC6) had been shown to suppress CGG 90 induced rough eye. Knockdown of autophagy by Atg12 RNAi had no effect on suppression of neurodegeneration by HDAC6, suggesting HDAC6 exerted protective effects by an autophagy-independent mechanism, which fits well with our findings.
In most neurodegenerative diseases, which are triggered by formation of aggregates, rapamycin or autophagy is sufficient to decrease the accumulation of mutant proteins and improve neurodegenerative phenotypes. Unlike other neurodegenerative disorders, rapamycin treatment enhanced neurodegeneration in FXTAS and activation of autophagy alone also proved to be ineffective at protecting against degeneration. These findings imply that FXTAS does not share the general pathogenic mechanism that aggregations of mutant proteins cause progressive neuronal dysfunction and loss. Therefore, we speculate that FXTAS, caused by elevated levels of mRNA, possesses unique aspects compared with other neurodegenerative diseases. It's prerequisite to distinguish FXTAS from other neurodegenerative diseases with the similar symptoms clearly in the diagnostic procedure, especially other ataxia disorders. Importantly, treatment of those patients should be cautious unless accurately diagnosed as rapamycin, or its analogues, may possibly bring about an effect opposite to the one intended.
Overexpression of fragile X premutation-length CGG repeats in mice or Drosophila could lead to pathological changes similar to patients, including FXTAS and fragile X-associated primary ovarian insufficiency (FXPOI) [4, 5, 6, 7, 8, 29] . In FXPOI mice model, significant reductions of phosphorylated AKT and mTOR were observed in ovaries [29] . Our findings definitely suggest that activating AKT/mTOR pathway can improve symptoms of FXTAS. Since both FXTAS and FXPOI result from toxicity of rCGG repeats, we reason that FXTAS and FXPOI share similar therapeutic intervention mechanisms and that, to some extent, the development of mTOR activators will be beneficial to them.
In FXTAS patients, the neuropathological hallmark is the presence of eosinophilic and ubiquitin-positive intranuclear inclusions, in both neuronal and astrocytic nuclei, distributed throughout the cortex and brain stem [2, 30] . FMR1 mRNA and more than 20 protein components have been identified within the intranuclear inclusions [31, 32, 33, 34] . FMR1 mRNA arrests those RNA binding proteins (RBPs) within inclusions and prevents them from performing normal function, which is considered the principal cause of neurotoxicity. Activation of PI3K/AKT/ mTOR signaling pathway has been proven to positively regulate expression of certain protein components in inclusions, such as myelin basic protein (MBP), 29,39-cyclic nucleotide 39-phosphodiesterase (CNPase) [35, 36, 37] , vimentin [38, 39, 40, 41, 42] , heterogeneous nuclear ribonucleoproteins (hnRNPs) [43] , glial fibrillary acidic protein (GFAP) [44] , HSP27 and HSP70 [45, 46] . Since those intra-inclusions proteins are positively regulated by AKT/ mTOR pathway, it's rational that activation of mTOR signaling exerts remission of neurodegenerative phenotypes through increasing protein synthesis. Additionally, aB-crystallin, a small heat shock protein also identified within the intranuclear inclusions of FXTAS, has been found to increase phosphorylation of AKT and mTOR, and to activate the PI3K/AKT/mTOR signaling pathway [47] . Thus, the correlation between mTOR and protein components within conclusions needs to be further explored.
In summary, using a FXTAS Drosophila model carrying human FMR1 premutation alleles, we showed that rapamycin could not ameliorate but rather exasperates rCGG 90 induced neurodegenerative phenotypes via an autophagy-independent mechanism, and demonstrated that rapamycin didn't increase rCGG 90 -mediated neurotoxicity. Moreover, we revealed that activating mTOR signaling could suppress neurodegeneration. Consequently, our results explicitly suggest that FXTAS should be distinguished from other neurodegenerative disorders due to its unique pathogenic mechanism. Our findings also strongly support the AKT/mTOR signaling pathway as a potential therapeutic target for FXTAS, particularly the downstream substrates S6K and 4E-BP1. Further study will be necessary to identify specific downstream proteins of mTOR and to evaluate if they could restore neurodegenerative phenotypes of FXTAS.
Materials and Methods
Fly stocks and husbandry
Fly culture and crosses were performed on standard food according to standard procedures and raised at 25uC. UAS-CGG 90 -EGFP and UAS-EGFP used in this study were described in Jin et al [4] . GAL4 were obtained from Bloomington Drosophila Stock Center. Fly lines of AKT/mTOR signaling were obtained from Bloomington Drosophila Stock Center and Vienna Drosophila RNAi Center.
Drugs treatment
Rapamycin (Sangon) was dissolved in DMSO (Sigma) and added to standard food at appropriate concentrations (1 nM, 10 nM, 100 nM, 1 mM, 2.5 mM, 5 mM, 50 mM, 200 mM, 400 mM). DMSO alone was used as a control.
Rilmenidine (Sigma) was dissolved in DMSO and added to standard food at appropriate concentrations (10 nM, 100 nM, 1 mM, 10 mM). DMSO alone was used as a control.
The genotypes are: GMR-GAL4.CGG 90 (a, g), GMR-GAL4.CGG 90 Scoring ommatidial degeneration All the genotypes presented here exhibit highly uniform retinal phenotypes. We modified scoring criteria by Pandey UB [48] for proteasome impaired flies and SMBA Drosophila to apply quantitative analyses for FXTAS Drosophila in view of ommatidial phenotypes observed under light microscopy. Thousands of FXTAS flies, control flies and flies with CAG repeats were scored and our objective criteria could reflect eye phenotype truthfully. Eyes were examined and given points for the presence or absence of four phenotypes: loss-of-pigmentation, neuron death (escharosis), retinal collapse, and ommatidial fusion. Points were assigned on the following scale: 1 point was given for each phenotype present; 2 points were given if the affected area involved more than 15% of the eye; 3 points were given if the affected area involved more than 40% of the eye; and 4 points were given if the affected area involved more than 65% of the eye. Additionally, scores for neuron death (escharosis) were given twice as it was a critical feature. A higher point stands for a more severe phenotype. All the scoring analyses were performed by three persons in a double-blind method and the scoring results were completely consistent. For each genotype, over 200 4 day old flies (.300 in most cases) were examined. Comparisons were made using Student's t-test or Mann-Whitney test.
LM and SEM
For light microscopy (LM) images, whole flies were analyzed with an OLMPUS DP72 microscope. For scanning electron microscopy (SEM) images, whole flies were analyzed with an JEOL JSM-6360-LA scanning electron microscope.
Locomotion assay
As described previously by Qurashi A [49] , homozygous progeny of 1 day old male flies were collected for locomotion assays. All the genotypes used to test locomotion were crossed with NRV2-GAL4. A Drosophila Activity Monitor (DAM) system (TriKinetics) was used to continuously monitor the locomotion. For each individual genotype, we simultaneously monitored the locomotion of at least 32 flies. Flies crossed the infrared beam and generated interruptions which were recorded as the activity of flies within 30 minutes. The readings were collected and analyzed for locomotor activity.
RT-PCR and Real-time PCR
TRIzol (AmbionH) was used to isolate total RNA from Drosophila. RNA was reverse-transcribed using iScript TM cDNA Synthesis Kit (BIO-RAD). Quantitative Real-time PCR was performed with the iQ TM SYBRH Green Supermix (BIO-RAD) in the CFX96 TM Real-Time System (BIO-RAD) using EGFPspecific primers. Actin-specific primers were used as control.
Western blotting
Protein lysis buffer (10 mM Tris-HCl, 150 mM NaCl, 30 mM EDTA, 0.5% Triton X-100, 1 mM PMSF, 16 protein inhibitors cocktail, 16 phosphatase inhibitors cocktail) was used to isolate total proteins from heads of Drosophila. Anti-phospho-p70 S6 Kinase (Thr398) (Cell Signaling) and anti-phospho-4E-BP1 (Thr37/46) (Cell Signaling) were used at a dilution of 1:1000. Anti-b-actin (Abcam) (control) was used at a dilution of 1:10000. Detection was performed with ECL (GE Healthcare).
